Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The collaboration combines SIRION’s adeno-associated virus (AAV) vectors for type 1 and type 2 diabetes gene therapy and expertise in viral vector development and production with CRG’s deep knowledge of genetic regulatory mechanisms.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Endocrinology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Sirion Biotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration February 16, 2022